Welcome to our dedicated page for PAVmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PAVmed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PAVmed's regulatory disclosures and financial reporting.
PAVmed Inc. filed a preliminary proxy for a special meeting on December 5, 2025 to seek approval for a reverse stock split and a reduction in authorized common shares.
The proposal authorizes a reverse split at a ratio between 1‑for‑10 and 1‑for‑30, with the exact ratio set later by the Board, and reduces authorized common stock from 250,000,000 to 25,000,000. Fractional shares will not be issued; any fraction will be rounded up to one whole share. The reverse split’s effectiveness is conditioned on obtaining consent from the holder of the Series C Preferred Stock.
The Board cites two goals: regaining Nasdaq minimum bid price compliance and potentially broadening investor access. As of October 15, 2025, 26,678,690 common shares were outstanding. The record date is October 23, 2025. Approval of the reverse split requires a majority of the outstanding capital stock and a separate majority of outstanding common stock. An adjournment proposal is also on the ballot to allow additional time to solicit votes if needed.
PAVmed Inc. director Ronald M. Sparks reported a grant of 150,000 restricted shares on 09/30/2025. The shares were issued at a price of $0 and carry a single vesting date of May 20, 2028. After the grant, the reporting person beneficially owns 215,000 shares in total. The restricted stock is subject to forfeiture if the required service period is not completed.
Debra White, a director of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025. The shares were issued at a price of $0 and, after the grant, Ms. White beneficially owns 215,000 shares. The restricted stock vests on May 20, 2028 and is subject to forfeiture if the required service period is not completed.
Timothy E. Baxter, a director of PAVmed Inc. (PAVM), received a grant of 150,000 restricted shares of common stock on 09/30/2025. After the grant, Mr. Baxter beneficially owned 215,000 shares in total. The restricted shares vest on a single date, May 20, 2028, and are subject to forfeiture if the required service period is not completed. The award was made under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and was reported on a Form 4.
Michael J. Glennon, a director of PAVmed Inc. (PAVM), was granted 150,000 restricted shares on 09/30/2025 under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a reported price of $0. After the grant his total beneficial ownership is reported as 231,667 shares. The restricted shares vest on May 20, 2028 and are subject to forfeiture if the required service period is not completed. The Form 4 was signed by power of attorney on 10/02/2025.
Sundeep Agrawal, a director of PAVmed Inc. (PAVM), reported an acquisition of 150,000 shares of common stock on 09/30/2025 via restricted stock granted under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The shares carry a single vesting date of May 20, 2028 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person’s beneficial ownership is reported as 162,195 shares. The Form 4 was signed by power of attorney on 10/02/2025.
PAVmed Inc. (PAVM) reported a Form 4 showing that Michael A. Gordon, the company's General Counsel, was granted 150,000 shares of common stock on 09/30/2025. The award is restricted stock issued under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carries a single vesting date of May 20, 2028. The shares have a reported acquisition price of $0 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person beneficially owns 150,000 shares directly. The form is signed by the reporting person on 10/02/2025.
PAVmed Inc. (PAVM) reporting person Dennis M. McGrath, who is identified as President and CFO, received a grant of 150,000 shares of restricted common stock on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carry a single vesting date of May 20, 2028; they are subject to forfeiture if the required service period is not completed. The Form 4 shows 200,834 shares beneficially owned by the reporting person after the transaction. The reported transaction lists a price of $0, indicating these were restricted shares rather than a cash purchase. The filing was executed by power of attorney and dated 10/02/2025.
Dr. Lishan Aklog, Chairman and CEO of PAVmed Inc. (PAVM), reported on Form 4 the grant of 150,000 restricted shares on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a $0 purchase price and vest on May 20, 2028, subject to forfeiture if service requirements are not met. After the transaction Dr. Aklog directly beneficially owns 228,418 shares and indirectly holds additional positions: 154 shares via his daughter, 152 via his son, 297,105 through Pavilion Venture Partners LLC (of which he is sole manager), and 1,333 through HCFP/AG LLC (co-managed). The filing was signed by power of attorney on 10/02/2025.
Shaun O'Neil, Chief Operating Officer of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025 under the company’s Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The restricted shares carry a $0 purchase price and vest on May 20, 2028, and are subject to forfeiture if the required service period is not completed. After the grant, the reporting person beneficially owned 167,933 shares. The filing was reported on Form 4 and signed by power of attorney on 10/02/2025.